Oct 2026· Bone Marrow Transplantation· 0 citations· 28 references
Medicine
TL;DR
LT is a feasible option for selected patients with end-stage LONIPCs, with long-term survival comparable to that reported for LT performed for other indications, and HLA-mismatched donor transplantation and corticosteroid use at LT were associated with inferior survival.
Background/Objectives: Hematopoietic cell transplantation (HCT) is the only established curative option for sickle cell disease (SCD), yet the optimal timing in pediatric cohorts remains incompletely defined. Methods: We retrospectively analyzed all patients under 20 years with SCD who underwent HCT at the University H...
C. Nazon, Chloé Gerber, Alexandra Salmon et al.· Journal of Clinical Medicine· 0 citations
Secondary failure of platelet recovery (SFPR) poses a significant risk for life-threatening complications following hematopoietic stem cell transplantation (HSCT). However, the incidence, clinical outcomes, and risk factors associated with SFPR in the context of allogeneic HSCT (allo-HSCT) for pediatric patients with a...
Yue Shang, Yuan-Yuan Ren, Li-Peng Liu et al.· Clinical Hematology Internat...· 0 citations
INTRODUCTION
Long-term outcomes of allogeneic hematopoietic cell transplantation (HCT) are improving, increasing the relevance of secondary malignancies, including lung cancer. The clinical utility of immune checkpoint inhibitors (ICIs) in this setting remains unclear and concerns regarding graft-versus-host disease (G...
M. Rost, C. Wehr, Miriam Mozaffari Jovein et al.· Lung Cancer· 0 citations
BACKGROUND
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for malignant and non-malignant diseases; however, primary graft failure (GF) is a life-threatening complication, particularly with the increasing use of alternative donors and reduced-intensity conditioning (RIC) str...
M. Daniel, Melissa Panesso Romero, María Isabel Benítez Carabante et al.· Transplantation and Cellular...· 0 citations
BACKGROUND
Single living-donor lobar lung transplantation (LDLLT) from the same donor as prior hematopoietic stem cell transplantation (HSCT) represents a unique immunologic setting because of donor-cell chimerism. However, data regarding immunosuppressive management and long-term outcomes in this setting remain limite...
Tatsuaki Watanabe, T. Hirama, Tsuyoshi Ryuko et al.· Transplantation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.